Synergy CHC Business Summary

Synergy CHC Corp. (SNYR) operates as a high-margin consumer health and wellness platform, generating revenue primarily through the omni-channel distribution of proprietary brands across the cognitive health, weight management, and functional beverage segments. The company’s business model leverages a robust retail footprint—including partnerships with Costco, Walmart, and Amazon—alongside a direct-to-consumer e-commerce strategy. Its primary revenue drivers are FOCUSfactor, a leading brain-health supplement, and Flat Tummy, a lifestyle brand focused on women’s nutritional goals. As of early 2026, Synergy is aggressively pivoting toward the functional beverage market with its FOCUSfactor Focus + Energy ready-to-drink line, aiming to capitalize on higher purchase frequencies and retail velocity. In the competitive landscape, Synergy contends with diversified consumer health peers such as MediciNova, OKYO Pharma, and Scilex, as well as specialized supplement brands like Neuriva. Within this peer group, Synergy distinguishes itself as a transition-stage growth company, maintaining 11 consecutive quarters of profitability and gross margins near 70%. Leadership is spearheaded by Chairman and CEO Jack Ross, an experienced entrepreneur and business builder who has led the company since its 2014 inception and overseen the acquisition of eight distinct brands. He is supported by President Alfred Baumeler, a CPG marketing veteran with previous leadership roles at Natrol and Healthy Natural Systems, and Chief Financial Officer Jaime Fickett, who was appointed in December 2024 following a decade-long tenure as the company’s SVP of Finance. The executive team was further strengthened in late 2025 with the appointment of Pedro Colmenares as Director of Sales & Marketing for Latin America to drive international expansion. The company’s strategic direction is guided by a board that includes former Costco executive Teresa Thompson and independent director Nitin Kaushal. Notable institutional backing is provided by Knight Therapeutics Inc., Heartland Advisors, and Gratia Capital, which collectively signal strong market confidence in Synergy’s beverage-led growth thesis for 2026.